Patients with advanced melanoma who received fecal microbiota transplants using healthy donor stool alongside standard immunotherapy survived more than four years, according to final results from an ...

This trial represents the first major advancement in second-line GIST treatment in over two decades, potentially transforming the therapeutic landscape. Cogent Biosciences announced positive results ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

Growth hormone receptor (GHR) signaling in bladder cancer is associated with advanced tumor stages and poor survival outcomes. High GHR expression in tumors up-regulates genes involved in drug ...

Newly analyzed data from Japan adds to the evidence that COVID-19 may increase the risk of shingles.

Managed Healthcare Executive interviewed OneHome’s Noel Gilliam, Vice President of Value-Based Product Design, to discuss the ...